Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 24 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
B&B PHARMA from Beersel, company number BE0554988666, closed financial year 2025 with a result of € 82,128 after tax. For that financial year B&B PHARMA recorded a gross margin of € 135,521 and equity of € 244,361. Compared with financial year 2024, the result moved from € 30,221 to € 82,128. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on October 5, 2026.
€ 244,361
▲ 15% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 82,128
▲ 172% vs 2024
Profit after tax over the fiscal year.
€ 9,320
▼ 9% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 50,000 paid out
61 % of the profit went to the shareholders, the rest stayed in the company.
Debts at end 2025
€ 386,093
▼ 16% vs 2024
€ 101,400 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 107,738
▲ 77% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 8,634
▲ € 8,389 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 236,558 | € 364,247 | € 138,393 | € 135,521 | ▼ 2% |
| Profit after taxes | € 169,369 | € 341,495 | € 30,221 | € 82,128 | ▲ 172% |
| Equity | € 40,516 | € 382,011 | € 212,233 | € 244,361 | ▲ 15% |
| Total debts | € 823,536 | € 519,923 | € 648,679 | € 567,075 | ▼ 13% |
| Cash | € 15,124 | € 7,028 | € 10,265 | € 9,320 | ▼ 9% |
| Land & buildings | € 183,088 | € 170,883 | € 158,677 | € 146,471 | ▼ 8% |
| Retained profit | € 21,916 | € 363,411 | € 193,633 | € 225,761 | ▲ 17% |
| Dividend | € 278,000 | € 0 | € 200,000 | € 50,000 | ▼ 75% |
| Bank debt | € 531,732 | € 480,499 | € 461,644 | € 386,093 | ▼ 16% |
| Balance sheet total | € 864,052 | € 901,935 | € 860,912 | € 811,436 | ▼ 6% |
Key figures of B&B PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to B&B PHARMA?
What happened at B&B PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 82,128 (▲ 172% vs 2024). filed late Source: NBB ↗
- New establishment in Ukkel. KBO
- BOULAL Nassima BOULAL became a director. NBB
- Emmanuel BALTHAZAR became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 169,369 profit in 2022 to € 82,128 profit in 2025.
Paid € 207,570 in corporate taxes since 2022.
Best year ever: 2023, with € 341,495 profit.
Paid out € 528,000 in dividends to the owners in total.
Management
Behind B&B PHARMA are BOULAL Nassima BOULAL and Emmanuel BALTHAZAR . It owns 100% of GAMA MEDICAL itself.
Directors
According to the 2025 annual accounts
BOULAL Nassima BOULAL
Director
since 2014
since 2014
Establishments
Establishment units
Physical locations of this company
Blarenveld 18
1650 Beersel
Gulden Kasteelstraat 14
1180 Ukkel
Active since 2 July 2014
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0554.988.666
- VAT number
- BE 0554.988.666
- Registered office
- Blarenveld 18, 1650 Beersel
- Names & denominations
- B&B PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 2 July 2014
- Peppol
- Active · Active since 6 Jan 2026
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van holdings
Holdings